Working… Menu

Post-market Surveillance Study With the HYPERION Hip Endoprosthesis System in Defect Reconstruction

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03382665
Recruitment Status : Terminated (CE mark will not be renewed, PMCF data no longer required)
First Posted : December 26, 2017
Results First Posted : August 21, 2020
Last Update Posted : August 21, 2020
Information provided by (Responsible Party):
Zimmer Biomet

Brief Summary:
The study is a multi-center, prospective, non-controlled, consecutive cohort post market surveillance study. The objective of this study is to obtain survival and clinical outcome data on the Hyperion® system in primary and revision total hip arthroplasty.

Condition or disease
Osteoarthritis Avascular Necrosis Rheumatoid Arthritis Functional Deformities Pseudoarthrosis Revision of Endoprosthesis-treated Hips Fracture, Proximal Humeral Provision of Non-endoprosthetic Previous Operations of the Hip Joint (e.g., Transposition Osteotomies) Femur Fracture Pseudarthrosis Trochanteric Fractures Bridging of Large Bone Defects Revisions

Detailed Description:

This multi-center, prospective, non-controlled, consecutive cohort post market surveillance study will serve the purpose of confirming long-term safety and performance of the Hyperion® system. The performance of the Hyperion® THA System will be evaluated using standard scoring systems (Merle d'Aubigné Score, HOOS Score). Safety will be evaluated by adverse event reporting.

The study will be performed at 6 sites, enrolling in total 70 patients. Follow-up visits are planned after 3 to 6 month, 1, 2 and 5 years. The scores will be filled in pre-operatively and post-operatively until 5 years. In order to obtain mid- to long-term patient satisfaction data the patient questionnaire will be send to the patient at 7 and 10 years, additionally. Xrays will be done pre-operatively, immediate post-operatively and at each of the Follow-up visits.

Layout table for study information
Study Type : Observational
Actual Enrollment : 70 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Prospective, Multi - Centre Clinical Evaluation of the Performance and Safety of the HYPERION Hip Endoprosthesis System in Defect Reconstruction
Actual Study Start Date : January 2010
Actual Primary Completion Date : August 2017
Actual Study Completion Date : March 2018

Primary Outcome Measures :
  1. Pain and Walking Ability Determined by a Merle d' Aubigné Score Increase of >4 Points. [ Time Frame: baseline/Pre-op and 2 years (+/- 2 months) ]

    Pain and walking ability determined by a Merle d' Aubigné Score (MdA) increase of >4 points compared to the pre-operative score points.

    The patients were evaluated by the Merle d'Aubigné hip score, which evaluates pain, gait and mobility, on a scale of 1 to 6 for each item, where 1 indicates the worst and 6, the best state of the patient. The value of each item is summed to a total score. The total minimum score reached is 3, and the maximum is 18. Higher scores mean a better outcome.

  2. Implant Survival Measured by the Number of Revisions. [ Time Frame: 2 years (+/- 2 month) ]
    Implant survival is measured by the number of revisions and analysed by the Kaplan Meier method.

  3. WOMAC Score Value Decrease at 2-years in Min. 25 Points Compared to the Pre-operative WOMAC Score Value [ Time Frame: baseline/Pre-op and 2 years (+/- 2 months) ]

    at 2-years post op, WOMAC score (Western Ontario and McMaster Universities Arthritis Index) has to be at least 25 points lower compared to preop values

    Scale: min 0-Max 100; Higher values mean worse outcome

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Because of the studiesindications it is assumed that patients have a relatively high (> 60 Jahre) age at the time of their operations. Therefore a higher letality and a higher drop-out-rate is expected compared to study populations of primary hip replacement. To reach the necessery power for this clinical study at least 70 patients should be recruited.

Inclusion Criteria:

  • Patient age at least 18 years
  • Fully conscious and capable patients
  • Signed informed consent
  • Stationary treatment
  • Merle d'Aubigné < 12 Points, WOMAC Score > 25 Points
  • Patients with at least one of the following indications:

Indications for primary hip replacement:

  • Non-inflammatory diseases of the joints such as osteoarthritis and avascular necrosis (head necrosis)
  • Rheumatoid arthritis
  • Functional deformities
  • Provision of non-endoprosthetic previous operations of the hip joint (e.g., transposition osteotomies)
  • Treatment of pseudarthrosis, femoral neck and trochanter fractures, as well as fractures of the proximal femur affecting the head, which can not be treated by other techniques

Revision THA:

  • Revision of endoprosthesis-treated hips as a result of septic or aseptic loosening, sub- and periprosthetic fractures or material failure (eg fracture of the prosthesis)
  • Bridging of large bone defects (precondition: suitable proximal bone situation for a stable anchorage), i.e. for tumors

Exclusion Criteria:

  • Infections
  • Patients under 18 years
  • Pregnant or breastfeeding patients
  • Known alcohol abuse (at least 20 g alcohol per day for women and at least 40 g per day for men) or drug abuse
  • Legal incapacity or restricted capacity
  • Participation in another clinical trial within the last 30 days or planned participation in another clinical trial within the next 3 months
  • Patients who are unable to attend to follow-up

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03382665

Layout table for location information
Helios Klinik Hildesheim
Hildesheim, Germany, 31135
Klinikum Osnabrück GmbH
Osnabrück, Germany, 49076
Asklepios Orthopädische Klinik Lindenlohe
Schwandorf In Bayern, Germany, 92421
Sponsors and Collaborators
Zimmer Biomet
Layout table for investigator information
Study Director: Paola Vivoda Zimmer Biomet
  Study Documents (Full-Text)

Documents provided by Zimmer Biomet:
Layout table for additonal information
Responsible Party: Zimmer Biomet Identifier: NCT03382665    
Other Study ID Numbers: BMETEU.CR.EU79.10
First Posted: December 26, 2017    Key Record Dates
Results First Posted: August 21, 2020
Last Update Posted: August 21, 2020
Last Verified: August 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Zimmer Biomet:
Revision total hip arthroplasty
Medical Device
Post Market Surveillance Study
Primary total hip arthroplasty
Additional relevant MeSH terms:
Layout table for MeSH terms
Fractures, Bone
Femoral Fractures
Hip Fractures
Shoulder Fractures
Wounds and Injuries
Pathologic Processes
Leg Injuries
Fractures, Ununited
Hip Injuries
Shoulder Injuries